Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
COSMO Pharmaceuticals N.V. ( (CH:COPN) ) has issued an announcement.
Cosmo Pharmaceuticals N.V. announced the approval of all agenda items at its 2025 general meeting, with shareholders endorsing a 2.5% increase in dividend distribution to EUR 2.05 per share. This decision reflects the company’s commitment to creating long-term value for its stakeholders, as emphasized by the Board Chairman and CEO. The company also plans to provide further insights into its projects at the upcoming Investor Day in Zurich.
The most recent analyst rating on (CH:COPN) stock is a Buy with a CHF113.00 price target. To see the full list of analyst forecasts on COSMO Pharmaceuticals N.V. stock, see the CH:COPN Stock Forecast page.
More about COSMO Pharmaceuticals N.V.
Cosmo Pharmaceuticals N.V. is a pharmaceutical company dedicated to revolutionizing healthcare by developing innovative products that address unmet needs. Operating in Healthtech/AI, Dermatology, Gastroenterology, and contract manufacturing and development, Cosmo collaborates with global partners like Medtronic and Sun Pharma. Founded in 1997, the company is headquartered in Dublin, Ireland, with branches in the USA and Italy, employing around 330 people.
Average Trading Volume: 26,654
Current Market Cap: CHF931.1M
Find detailed analytics on COPN stock on TipRanks’ Stock Analysis page.